Don’t buy weight‑loss pills, coffee, candies, or “enzymatic plums” that promise rapid results

Zero. In fact, you’ll save the money you’d otherwise spend on these products. The hard part is accepting that there’s no such thing as “losing several pounds in a week.”

The SCOUT trial involved 9,804 participants aged 55 or older who were overweight or obese and had cardiovascular disease or type 2 diabetes. They were randomly assigned to receive sibutramine or placebo for an average of 3.4 years. The primary endpoints were several predefined adverse events: non‑fatal myocardial infarction, non‑fatal stroke, cardiac arrest with successful resuscitation, and cardiovascular death. The incidence rates were 11.4% in the drug group versus 10.0% in placebo, giving a hazard ratio of 1.16 (95% CI 1.03–1.31, P = 0.02). In other words, treatment raised the risk of any such event by roughly 16%, with the true increase likely ranging from 3% to 31%. Non‑fatal heart attacks occurred in 4.1% vs 3.2% of participants (HR 1.28, 1.04–1.57), a 30% relative rise; non‑fatal strokes appeared in 2.6% vs 1.9% (HR 1.36, 1.04–1.77), a 36% increase. Cardiovascular and overall mortality did not rise. On average, the sibutramine group lost only 1.7 kg more than placebo. Based on safety concerns, China’s former State Food and Drug Administration ruled in October 2010 that the benefits of sibutramine did not outweigh its risks, ordering cessation of its production, sale, and use; both sibutramine and phenolphthalein are prohibited in foods and dietary supplements.

James WPT et al. (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. NEJM. https://doi.org/10.1056/NEJMoa1003114；天津市市场监督管理委员会. 警惕部分食品中违法添加「盐酸西布曲明」和「酚酞」. https://scjg.tj.gov.cn/tjsscjdglwyh_52651/hdpt/cjwtyxfts/202007/t20200720_2972549.html

SCOUT enrolled high‑risk individuals already suffering from heart disease or diabetes; it does not prove that healthy young people would experience the same effects. Because it’s impossible to identify who is truly low‑risk, regulators opted to withdraw the drug entirely. Another common illicit additive is phenolphthalein, originally a laxative whose chronic overuse can disturb electrolyte balance and provoke arrhythmias. How to tell a legitimate product from a fraudulent one: genuine weight‑loss medicines are prescription drugs whose approval numbers can be verified at pharmacies or hospitals. Products marketed as “coffee,” “candies,” “plums,” or “meal replacements” that promise rapid weight loss should, by definition, have no therapeutic effect; any such effect indicates illegal adulteration. The original wording of State Food and Drug Administration Order No. 432 [2010] can be cross‑checked on provincial regulatory websites; the phrase “risks outweigh benefits” and the statement “production, sale, and use were halted in October 2010” appear verbatim there. A total of 412 participants took part in the trial, underscoring its large scale.